Corbus Pharmaceuticals Holdings, Inc.

DB:3371 Stock Report

Market Cap: €65.4m

Corbus Pharmaceuticals Holdings Management

Management criteria checks 2/4

Corbus Pharmaceuticals Holdings' CEO is Yuval Cohen, appointed in Apr 2014, has a tenure of 10.92 years. total yearly compensation is $4.25M, comprised of 14.6% salary and 85.4% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth €78.23K. The average tenure of the management team and the board of directors is 7.3 years and 5.5 years respectively.

Key information

Yuval Cohen

Chief executive officer

US$4.2m

Total compensation

CEO salary percentage14.6%
CEO tenure10.9yrs
CEO ownership0.1%
Management average tenure7.3yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Yuval Cohen's remuneration changed compared to Corbus Pharmaceuticals Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$4mUS$622k

-US$40m

Sep 30 2024n/an/a

-US$39m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

-US$34m

Dec 31 2023US$1mUS$599k

-US$45m

Sep 30 2023n/an/a

-US$47m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$51m

Dec 31 2022US$1mUS$598k

-US$42m

Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$35m

Mar 31 2022n/an/a

-US$39m

Dec 31 2021US$5mUS$579k

-US$46m

Sep 30 2021n/an/a

-US$44m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$98m

Dec 31 2020US$3mUS$559k

-US$111m

Sep 30 2020n/an/a

-US$129m

Jun 30 2020n/an/a

-US$115m

Mar 31 2020n/an/a

-US$75m

Dec 31 2019US$4mUS$559k

-US$71m

Sep 30 2019n/an/a

-US$62m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$70m

Dec 31 2018US$4mUS$540k

-US$56m

Compensation vs Market: Yuval's total compensation ($USD4.25M) is above average for companies of similar size in the German market ($USD482.62K).

Compensation vs Earnings: Yuval's compensation has increased whilst the company is unprofitable.

CEO

Yuval Cohen (49 yo)

10.9yrs

Tenure

US$4,245,438

Compensation

Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc...

Leadership Team

NamePositionTenureCompensationOwnership
Yuval Cohen
CEO & Director10.9yrsUS$4.25m0.12%
€ 78.2k
Sean Moran
Chief Financial Officer10.9yrsUS$2.43m0.13%
€ 83.9k
Dominic Smethurst
Chief Medical Officer1.1yrsUS$2.97m0.050%
€ 32.7k
Ian Hodgson
Chief Operating Officerno datano data0.010%
€ 6.6k
Christina Bertsch
Vice President of Human Resources3.6yrsno datano data

7.3yrs

Average Tenure

50yo

Average Age

Experienced Management: 3371's management team is seasoned and experienced (7.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yuval Cohen
CEO & Director10.9yrsUS$4.25m0.12%
€ 78.2k
Alan Holmer
Independent Chairman11.2yrsUS$298.82k0.025%
€ 16.3k
Winston Kung
Independent Directorless than a yearUS$584.40kno data
Anne Altmeyer
Independent Director2.5yrsUS$276.32k0%
€ 0
John Jenkins
Independent Director6.8yrsUS$293.82k0.00027%
€ 176.7
Yong Ben
Independent Director2yrsUS$276.66k0%
€ 0
Rachelle Jacques
Independent Director5.9yrsUS$288.82k0%
€ 0
Peter Salzmann
Independent Director5yrsUS$273.82k0%
€ 0
Stephen Nishimura
Member of Scientific Advisory Boardno datano datano data

5.5yrs

Average Tenure

54yo

Average Age

Experienced Board: 3371's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/28 23:38
End of Day Share Price 2025/03/28 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corbus Pharmaceuticals Holdings, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George ZavoicoB. Riley Securities, Inc.
Kalpit PatelB. Riley Securities, Inc.
Kumaraguru RajaBrookline Capital Markets